Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02236273 · ClinicalTrials.gov registry record · NA
Interactive, Health Literacy Promoting Text Messages and HPV Vaccine Completion In Minority Adolescents
A NA study, sponsored by Columbia University.
- Completed
- Registry status
- NA
- Development phase
- 956
- Enrollment target
NCT02236273 is a NA study that has completed, run by Columbia University. The registered enrollment target is 956 participants.
The verdict
NCT02236273, a NA study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- NA
- Development phase
- 956 participants
- Enrollment target
Study Summary
Emerging communication technologies, such as text messaging offer low-cost, scalable opportunities to improve health literacy and promote healthy behaviors, such as vaccination. While the investigators reported the success of text message vaccine reminders, effects were limited by their untailored approach. The trans-theoretical model of behavior change supports tailoring interventions to an individual's stage of decision-making. Human papillomavirus (HPV) is the most prevalent sexually transmitted virus in the U.S. and can lead to genital warts, and cervical, anal and penile cancer. The three-dose vaccine is 90-100% efficacious. Minorities are at greatest risk for such cancers but have low HPV vaccine completion rates. Limited health literacy regarding the vaccine can affect series completion. The investigators will compare the effects of enhancing text message vaccination reminders with interactive, vaccine health literacy-promoting information tailored to vaccine decision making-stage on HPV vaccine series completion. The effects of these messages represent a new paradigm in interactive health communications.
Interventions
- BEHAVIORAL Conventional text message reminder
- BEHAVIORAL Enhanced text message reminders
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 956 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02236273
The ClinicalTrials.gov registry entry for NCT02236273 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 956 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Conventional text message reminder is the first listed.
NCT02236273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02236273 about?
NCT02236273 is a clinical study titled "Interactive, Health Literacy Promoting Text Messages and HPV Vaccine Completion In Minority Adolescents". Emerging communication technologies, such as text messaging offer low-cost, scalable opportunities to improve health literacy and promote healthy behaviors, such as vaccination. While the investigators reported the success of text message vaccine reminders, effects were limited by their untailored a...
What is the current status of trial NCT02236273?
This trial is currently completed. It is a NA study. The enrollment target is 956 participants. The study started on 2014-12. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02236273?
The interventions under investigation include: Conventional text message reminder (BEHAVIORAL), Enhanced text message reminders (BEHAVIORAL).
Who is sponsoring clinical trial NCT02236273?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.